CAT # Product Name Description
CPD100573 PF-05175157 PF-05175157 is a potent and selective inhibitor of both acetyl-CoA carboxylase isoform ACC1 located primarily in liver and adipose tissue and isoform ACC2 dominant in skeletal and heart muscle, with IC50 values of 27 nM and 33 nM, respectively. ACC inihibitors inhibit de novo lipogenesis and increase β-oxidation of long-chain fatty acids with potential for treatment of type 2 diabetes, hepatic steatosis, and cancer.
CPD100572 ND-646 ND-646 is-an allosteric inhibitor of the ACC enzymes ACC1 and ACC2 that prevents ACC subunit dimerization-to suppress fatty acid synthesis in vitro and in vivo. Chronic ND-646 treatment of xenograft and genetically engineered mouse models of NSCLC inhibited tumor growth. When administered as a single agent or in combination with the standard-of-care drug carboplatin, ND-646 markedly suppressed lung tumor growth in the Kras;Trp53-/- (also known as KRAS p53) and Kras;Stk11-/- (also known as KRAS Lkb1) mouse models of NSCLC. ND-646 had enhanced efficacy when combined with carboplatin, a common component of chemotherapeutic regimens used to treat human NSCLC.
CPD100571 CP-640186 CP-640186 is a potent inhibitor of mammalian ACCs and can reduce body weight and improve insulin sensitivity in test animals. CP-640186 has recently been shown to be a potent inhibitor of isoforms of mammalian ACCs with IC50 values of about 55 nM. This is currently the only reported potent inhibitor of mammalian ACCs. In cell cultures as well as in animal models, CP-640186 can reduce tissue malonyl-CoA levels, inhibit fatty acid biosynthesis, and stimulate fatty acid oxidation. Most importantly, CP-640186 can reduce body fat mass and body weight, and improve insulin sensitivity, validating ACCs as targets for antiobesity and antidiabetes drugs.
CPD1592 ND-630 ND-630 is an acetyl-CoA carboxylase (ACC) inhibitor; inhibits human ACC1 and ACC2 with IC50 values of 2.1 and 6.1 nM, respectively.
CPD5077 ND-646 ND-646 is an orally bioavailable and steric inhibitor of acetyl-CoA carboxylase (ACC) with IC50s of 3.5 nM and 4.1 nM for recombinant hACC1 and hACC2, respectively.

Contact Us


Latest News

  • Top 7 Trends In Pharmaceutical Research In 2018

    Top 7 Trends In Pharmaceutical Research I...

      Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

  • ARS-1620: A promising new inhibitor for KRAS-mutant cancers

    ARS-1620: A promising new inhibitor for K...

    According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...

  • AstraZeneca receives regulatory boost for oncology drugs

    AstraZeneca receives regulatory boost for...

    AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

WhatsApp Online Chat !